Novavax (NVAX) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Novavax (NVAX) over the past year, gaining 113.4% versus a gain of 23.7%. Over five years, URGN leads with a +117.3% price change compared with -93.2% for NVAX. Novavax is the larger company by market cap ($2.13 billion vs $1.82 billion), about 1.2 times the size.
Novavax converts more of its revenue into profit, with a net margin of 39.2% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | URGN |
|---|---|---|
| Share price | $12.93 | $37.22 |
| Market cap | $2.13B | $1.82B |
| 1-day change | +17.44% | +0.65% |
| YTD return | +63.84% | +57.90% |
| 1-year return | +23.71% | +113.39% |
| 5-year return | -93.20% | +117.27% |
| Forward P/E | — | 13.32 |
| EPS (TTM) | $-1.58 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.12B | $109.79M |
| Revenue growth (YoY) | +64.69% | +21.45% |
| Net income (latest FY) | $440.30M | $-153.49M |
| Gross margin | 93.50% | 88.66% |
| Operating margin | 40.30% | -113.73% |
| Net margin | 39.19% | -139.81% |
| 52-week high | $13.39 | $50.81 |
| 52-week low | $6.20 | $15.86 |
| Distance from 52-week high | -3.44% | -26.75% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +8.28% | +61.20% |
| Average volume | 5.21M | 849.01K |
| Shares outstanding | 164.95M | 48.88M |
| Employees | 749 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed NVAX by 89.7 percentage points over the past year.
- Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- Novavax grew revenue faster in its latest fiscal year (+64.69% vs +21.45%).
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
NVAX vs URGN FAQ
Which is bigger, Novavax or UroGen Pharma?
Novavax (NVAX) is larger, with a market capitalization of $2.13B compared with $1.82B for UroGen Pharma (URGN).
Which stock has performed better over the past year, NVAX or URGN?
URGN returned +113.39% over the past 12 months, compared with +23.71% for NVAX (price return, excluding dividends). Past performance does not predict future results.
Are Novavax and UroGen Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Novavax and Biotechnology: Pharmaceutical Preparations for UroGen Pharma.